InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,340.00
(
0.39%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.97
(
0.64%
)
Bitcoin
61,426.95
(
-0.30%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119944
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 221944

Monday, 11/05/2018 11:15:05 AM

Monday, November 05, 2018 11:15:05 AM

Post# of 252412
NVS—Slide #48 graphs 10-year price vs QALYs for eight approved rare-disease drugs. A trend line has been fitted to these eight data points, and AXVS-101 intersects the trend line at a (10-year) price of $4M, based on a 13.3 QALY estimate by NVS.

I would caution against over-analyzing this chart.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up